Professor of Medicine
Harvard Medical School
Clinical Director, Division of Infectious Diseases
Brigham and Women's Hospital
- Clinical trials of antiretroviral therapy
- Cost-effectiveness in HIV
- Complications of HIV therapy
- HIV therapy: when to start and what to start with
- Resistance primer for HIV clinicians
Dr Sax is the Clinical Director of the Division of Infectious Diseases at Brigham and Women's Hospital and an Assistant Professor of Medicine at Harvard Medical School, where he has been on the faculty since 1992. He is site Principal Investigator for Harvard Medical School's AIDS Clinical Trials Unit and is a member of the Cost Effectiveness of Preventing AIDS Complications (CEPAC) group at the Harvard School of Public Health. He maintains an active clinical practice in infectious diseases that focuses on HIV infection.
- Editor in Chief, AIDS Clinical Care
- HIV Medicine Association
- American Academy of HIV Medicine
- Massachusetts Medical Society
- Edward H Kass Award in Clinical Excellence (1993)
- Harvard-Longwood Infectious Disease Fellowship Award in Clinical Teaching (1997)
- Brigham Resident Mentorship Award (2002)
- Harvard College, AB (1982)
- Harvard Medical School, MD (1987)
- Brigham and Women's Hospital, Resident in Internal Medicine (1987-1990)
- Massachusetts General Hospital, Fellowship in Infectious Diseases (1990-1992)
- Colson AE, Keller MJ, Sax PE, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. AIDS. 2002;30:27-32.
- Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002;162:2478-2486.
- Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, Freedberg KA. Treatment of primary HIV infection: projection outcomes of immediate, interrupted, or delayed therapy. AIDS. 2002;31:27-37.
- Hadigan C, Meigs JB, Wilson PWF, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis. 2003;36:909-916.
- Hurtado RM, Sax PE. Antiretroviral therapy. In Libman H and Makadon JH (eds): HIV. American College of Physicians-American Society of Internal Medicine Press;2003:77-100.
- Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen D, Sax PE, Ukomadu C. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus (HIV)-1-infected individuals. Clin Infect Dis. 2003;36:1602-1605.
- Goldie SJ, Paltiel AD, Walensky R, Weinstein MC, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with HIV infection. Am J Med. 2003;115:632-641.
- Sax PE, Walker BD. Immunology of AIDS. In Goldman L and Bennett JC (eds): Cecil Textbook of Medicine, 22nd Edition. W.B. Saunders, 2004:2137-2139.
- Losina E, Pollock AC, Islam R, Sax PE, Freedberg KA, Walensky RP. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis. 2004;38:1613-1622.
- Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140:786-794.
- Ivers LC, Kim AY, Sax PE. Predictive value of cerebrospinal fluid EBV PCR for the diagonsis of HIV-related primary central nervous system lymphoma. Clin Infect Dis. 2004;38:1629-1631.
- Sax PE. Pulmonary complications of HIV infection. In Mandell GL, Bennett JE, Dolin (eds): Principles and Practice of Infectious Diseases, Churchill Livingston, 2005, in press.
An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management
Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2016.